193 related articles for article (PubMed ID: 26834107)
21. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
[TBL] [Abstract][Full Text] [Related]
22. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
23. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
24. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
25. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Kümler I; Palshof JA; Andersson M
Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
[TBL] [Abstract][Full Text] [Related]
27. Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S; Pickering L; Ellis P
J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
[TBL] [Abstract][Full Text] [Related]
28. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab in the Treatment of Breast Cancer.
Maximiano S; Magalhães P; Guerreiro MP; Morgado M
BioDrugs; 2016 Apr; 30(2):75-86. PubMed ID: 26892619
[TBL] [Abstract][Full Text] [Related]
30. Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.
Henry KE; Ulaner GA; Lewis JS
PET Clin; 2018 Jul; 13(3):423-435. PubMed ID: 30100080
[TBL] [Abstract][Full Text] [Related]
31. Targeting HER2 in Nuclear Medicine for Imaging and Therapy.
Massicano AVF; Marquez-Nostra BV; Lapi SE
Mol Imaging; 2018; 17():1536012117745386. PubMed ID: 29357745
[TBL] [Abstract][Full Text] [Related]
32. Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy.
Capala J; Bouchelouche K
Curr Opin Oncol; 2010 Nov; 22(6):559-66. PubMed ID: 20842031
[TBL] [Abstract][Full Text] [Related]
33. Targeting HER2 heterogeneity in breast cancer.
Hamilton E; Shastry M; Shiller SM; Ren R
Cancer Treat Rev; 2021 Nov; 100():102286. PubMed ID: 34534820
[TBL] [Abstract][Full Text] [Related]
34. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.
Henry KE; Ulaner GA; Lewis JS
PET Clin; 2017 Jul; 12(3):269-288. PubMed ID: 28576166
[TBL] [Abstract][Full Text] [Related]
35. Peptide Based Imaging Agents for HER2 Imaging in Oncology.
Ducharme M; Lapi SE
Mol Imaging; 2020; 19():1536012120960258. PubMed ID: 32957830
[TBL] [Abstract][Full Text] [Related]
36. Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.
Ge S; Li J; Yu Y; Chen Z; Yang Y; Zhu L; Sang S; Deng S
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770887
[TBL] [Abstract][Full Text] [Related]
37. Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach.
Zeng L; Yang K
J Ethnopharmacol; 2017 Mar; 199():68-85. PubMed ID: 28130113
[TBL] [Abstract][Full Text] [Related]
38. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer.
Tolmachev V; Orlova A; Sörensen J
Semin Cancer Biol; 2021 Jul; 72():185-197. PubMed ID: 33465471
[TBL] [Abstract][Full Text] [Related]
39. Nano-pharmaceutical formulations for targeted drug delivery against HER2 in breast cancer.
Sadat SM; Saeidnia S; Nazarali AJ; Haddadi A
Curr Cancer Drug Targets; 2015; 15(1):71-86. PubMed ID: 25564255
[TBL] [Abstract][Full Text] [Related]
40. PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.
McGale J; Khurana S; Huang A; Roa T; Yeh R; Shirini D; Doshi P; Nakhla A; Bebawy M; Khalil D; Lotfalla A; Higgins H; Gulati A; Girard A; Bidard FC; Champion L; Duong P; Dercle L; Seban RD
J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
